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All trans retinoic acid (ATRA) is a potent inducer of differentiation of HL-60 cell line. The pretreatment of the cells by compactin,
a competitive inhibitor of 3-hydroxy-3-methylglutaryl (HMG) CoA reductase, during 24hours, enhances the ATRA-induced cell
differentiation.At50nM,thepercentageof celldifferentiationis 34.9%±2and73%±2.96inthecontrolandcompactin-treatedcells,
respectively.Theremovalofcompactinbooststhelevelof HMG-CoAreductaseandthereforethebiosynthesisofsterolandnonsterol
isoprenoidcompounds.Theparticipationofsterolandnonsterolpathwaywastheninvestigated.Thesupplyofanexcessofcholesterol
(up to 80µg/ml of LDL) leads to a signiﬁcant decrease of cell differentiation by ATRA from 78% ± 0.1 to 54% ± 2.8. A concomitant
decreaseofcellgrowth(51%±6.4)wasobserved.Thepretreatmentofcellsbythegeranylgeranyltransferaseinhibitor(GGTI-298)has
no effect on the cell differentiation process. By contrast, the farnesyltransferase inhibitors (FTI-II and FTI-277) completely abolish
the ATRA-induced differentiation, thus conﬁrming the involvement of farnesylated proteins in the differentiation mechanism.
INTRODUCTION
Theretinoidsplayanimportantroleinregulatingabroad
range of biological processes such as growth differentiation
and development in a variety of cell types and tissues [1].
All trans retinoic acid (ATRA) exerts a potent differen-
tiating action on human myelogenous leukemia HL-60 cell
line and primary bone marrow cultures from patients with
acute myelogenous leukemia (AML) [2, 3]. One mechanism
for the differentiating activity of ATRA in cells involves the
RA nuclear receptors (RARs and RXR) [4], which have spe-
ciﬁc high-afﬁnity binding sites for ATRA and some of its
metabolites [5–7]. Other mechanisms may also be involved
in RA-induced differentiation including retinoic acid acyla-
tion [8, 9].
A potent differentiating action of ATRA on leukemic cell
line is accompanied by a marked cell growth inhibition, as
evidenced by an increase of cells in G0 and a reduction of
cells in S phase [10]. However, until now, no clear evidence
has been given to prove if both processes are independent
or closely related. Our work focused on a possible common
pathway based on mevalonate (MVA) metabolism.
Proliferation of cells is known to require at least 2 prod-
ucts synthesized from mevalonate: cholesterol and nonsterol
isoprenoid derivatives, including farnesylated proteins espe-
cially those of ras family [11].
HMG-CoA reductase functions as the rate-limiting
enzyme of the MVA pathway. It is highly regulated by a
negative feedback mechanism. Indeed, the sterols repress
transcription of the HMG-CoA reductase gene through a
short sequence in the 5  ﬂanking region of the gene desig-
nated SRE-1 [12–14]. Nonsterol and sterol compounds con-
trol HMG-CoA reductase translation [15] and degradation
rate [16, 17].
Mevalonate homeostasis is achieved through (i) sterol-
mediated feedback repression of the genes for HMG-CoA
synthetase, HMG-CoA reductase, and the LDL receptor
and (ii) posttranscriptional regulation of HMG-CoA reduc-
tase [11].
The studies have identiﬁed a number of proteins with
mevalonate-derived prenyl groups attached post-transla-
tionally[18,19].Growth-regulatingp21rasproteinsencoded
byras protooncogenesandoncogenesarecovalentlyattached
tofarnesylresidueswhichanchorthemtothecellmembrane.
In the search for MVA-derived compounds involved in
growth control, much attention has been aimed at preny-
lated proteins [20].Among them,Ras proteins have attracted
special interest [21]. Indeed, p21ras proteins are involved
in cell growth, and oncologically mutated forms of ras are
found in a wide variety of human tumors [18, 22, 23]. In-
terestingly, Prendergast et al. [24] reported that inhibition
of ras farnesylation with farnesyltransferase inhibitors leads
to transformed phenotype reversion. However,these authors
suggested that other prenylated proteins than Ras might be
implicated in this mechanism.
Ras proteins are processed through a series of reactions
that result in either farnesylation or geranylgeranylation at a
cysteine residue at the fourth amino acid position from the
carboxyl-terminal end [25].
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(γ subunit), nuclear lamins (A and B, and rhodopsin ki-
nase,amongothers,requirestheircovalentattachmentto C15
(farnesyl) or C20 (geranylgeranyl) isoprenoids derived from
mevalonate [11, 26, 27]. Isoprenylation-dependent mem-
brane anchorage and subcellular localization of Ras protein
is often required for their maturation and function[26–29].
The farnesylated proteins are necessary for cell growth
[18, 19]. On the other hand, induction of differentiation is
well known to parallel a decrease of cell growth [10]. Here,
we put in evidence that nonsterol compounds, derived from
mevalonate pathway, could be a common key element in-
volved in these two processes.
MATERIALS AND METHODS
Cellcultureandreagents
HL-60promyelocyticleukemiccells(AmericanTypeCul-
ture collection, Rockville, MD) were grown in RPMI 1640
(GIBCO, France) supplemented with 15% heat inactivated
fetal calf serum (GIBCO, France) and 2mM L-glutamine
in a humidiﬁed atmosphere of 95% air, 5% CO2. ATRA,
from Hoffman-La Roche, France, was dissolved in dimethyl-
sulfoxide(DMSO)ataninitialstockconcentrationof 0.01M
and stored at −20◦C. At the time of analysis all samples were
allowed to thaw in the dark at room temperature and diluted
at the appropriate concentration in RPMI 1640 medium. In
all cell cultures, the concentration of DMSO never exceeded
0.01%. Compactin was obtained from Sigma and Farnesyl-
transferaseinhibitorIIfromCalbiochem.Farnesyltransferase
inhibitor 277 (FTI-277) and geranylgeranyltransferase in-
hibitor 298 (GGTI-298) were kind gifts from Said M. Sebti
and Michelle A. Blaskovich (University of South Florida, H.
Lee Mofﬁtt Cancer Center & Research Institute).
Low-densitylipoprotein(LDL)preparation
Human LDL was prepared by ultracentrifugation using
a Beckman TL 100 ultracentrifuge and a Beckman TL 100.2
ﬁxed angle rotor [30].
Inductionofcelldifferentiation
H L - 6 0c e l l sw e r es u s p e n d e di ng r o w t hm e d i u ma t10 ×
104 cells/mlinthepresenceorabsenceof theindicatedagent.
The cell viability was assessed by trypan blue exclusion test.
DifferentiationwasestimatedbyNBTreductionaspreviously
described [31]. A minimum of 300cells was counted and the
percentageof differentiation(i.e.,percentageof NBTpositive
cells) was calculated.
Westernblotting
Cellswerelysedwith 2×Laemmlisamplebuffer.Samples
(106 cells/100 µl) were boiled, sheared, and clariﬁed by cen-
trifugation in a microcentrifuge prior to storage at −20◦C.
Samples were separated on a 12.5% SDS polyacrylamide gel
and electrophoretically transferred to nitrocellulose mem-
brane. Membrane was blocked for 2hours in TBS (50mM
Tris, 150mM NaCl, pH 7.5) containing 0.1% Tween 20
(TBST) and 5% powdered milk before antibody addition.
Membrane was probed with monoclonal antibody directed
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Figure 1: Effect of ATRA on HL-60 cell differentiation. HL-60 cells
wereincubatedfor24hoursinfoetalcalflipoproteindeprivedserum
(LDS medium) supplemented with compactin (2µM). Then, they
werewashedinphosphatebufferedsalineandculturedduring5days
in LDS medium containing increasing concentrations of ATRA ().
The control cells were cultured during 5days in FCS medium con-
taining increasing concentrations of ATRA ( ).At day 5,cell differ-
entiation was determined by NBT reduction and viable cell number
asdeterminedbyTrypanblueexclusion.Insert:Effectoncellgrowth.
ATRA-treated cells 50nM () and control cells ().
against H-ras, or with monoclonal antibody directed against
K-ras or with polyclonal antibody directed against N-ras,a l l
fromTebu-SantaCruz,France.Detectionwasperformedwith
ECL chemiluminescence system (Amersham).
RESULTS
EffectofATRAondifferentiation
ofcompactin-HL-60treatedcells
The presence of compactin and cholesterol-deprived
medium (LDS) had no effect on the basal differentiation
activity of HL-60 cells. The treatment of HL-60 cells with
ATRAinducedagradualincreaseofdifferentiatedcells.When
endogenous cholesterol synthesis was inhibited,in a ﬁrst step
for 24hours by incubation in LDS containing compactin
(2µM),thentheremovalofcompactininducedanincreaseof
the sterol and nonsterol pathways, a possible consequence of
the overexpression of HMG-CoA reductase, ATRA induced
cell differentiation but the effect was more pronounced in
the cells temporarily treated with compactin. At 50nM,
ATRA induced, respectively, 34.9% ± 2 and 73% ± 2.96 of
cell differentiation (Figure 1), in the control and compactin-
treatedcells,whereas1000nMwasrequiredtoobtain 80%±4
in control cells.
Furthermore, at 50nM of ATRA, a strong increase
of growth inhibition was observed in the differentiated
compactin-treatedcellscomparedwithcontrolcells(80.5±5
versus 132.5 ± 30) (Figure 1).110 Naima Gueddaria-Pouzols et al. 1:3 (2001)
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Figure2:Effectofhigherlow-densitylipoproteinconcentrationson
growthanddifferentiationof HL-60cellsbyATRA.HL-60cellswere
incubatedduring5dayswith1µMATRAandincreasingconcentra-
tions of LDL. Differentiation as determined by NBT reduction (◦)
and viable cell number as determined by Trypan blue exclusion ().
0 5 10 20 25
0
5
10
15
20
25
30
35
40
45
IFT (µM)
D
i
f
f
e
r
e
n
t
i
a
t
i
o
n
 
(
%
)
Figure 3: Effect of farnesyltransferase inhibitors on differentiation
of HL-60cellsbyATRA.HL-60cellswerepretreatedwithincreasing
concentrations of FTI-II (•) or FTI-277 (◦). After 24hours, The
ATRA (1 µM) was added to culture medium. Cell differentiation
was determined at day 4.
Effectofincreasingconcentrationsoflow-density
lipoproteinondifferentiationofHL-60
cellsbyATRA
In order to test the cholesterol effect on ATRA-induced
cell differentiation, the cells were incubated in the presence
of ATRA (1µM) and increasing concentrations of LDL, up
to 80 µg/ml. Under such conditions, the differentiation of
ATRA-treated cells was decreased from 78% to 54% ± 2.8.
Interestingly, a concomitant decrease of cell growth (48%)
was evidenced in the presence of high concentrations of LDL
(Figure 2).
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Figure 4: Effect of prenylation protein inhibitor on differentiation
of HL-60 cells by ATRA. HL-60 cells were pretreated with 10µM of
GGTI-298 or FTI-II or FTI-277. After 24hours, The ATRA (1µM)
was added to culture medium. Cell differentiation was determined
at day 4.
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N-ras
K-ras
5 µM 10 µM
cont FTI-II FTI-277 GGTI-298
Figure 5: Inhibition of H-ras, N-ras, and K-ras prenylation by FTI-
II,FTI-277,andGGTI-298HL-60cellsweretreatedwith5or10µM
ofFTI-IIor10µMofFTI-277orGGTI-298for24hours.Celllysates
were analyzed by Western blotting with either a H-ras monoclonal
antibody or a N-ras polyclonal antibody or a K-ras monoclonal an-
tibody. Arrows,unprenylated ras bands.
Evidencefortheinvolvementofprenylatedproteins
inHL-60celldifferentiation
The cells were preincubated in the presence of the farsne-
syltransferase inhibitor II or farnesyltransferase inhibitor
FTI-277during24hours,thentreatedbyATRAduring3days
(Figure3).AstrongdecreaseofATRA-induceddifferentiation
was observed with increasing concentrations of both inhib-
itors. FTI-277 was a more potent inhibitor compared with
FTI-II(Figure3).Indeed,thedifferentiatingactivitybyATRA1:3 (2001) Up-regulation of ATRA-induced cell differentiation by farnesylated proteins 111
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Figure 6: Interaction between mevalonate pathway and retinoic acid-induced differentiation.
was totally abolished at 25µM of FTI-277 (Figure 3) and
40µM of FTI-II (data not shown). These results conﬁrmed
the involvement of the nonsterol mevalonate pathway in cell
differentiation.
When the cells were preincubated in the presence of
10µM of GGTI-298 during 24hours, then treated by ATRA
during 3days, no signiﬁcant result was observed com-
pared with control cells whereas, at the same concentration
(10µM), FTI-II and FTI-277 decrease ATRA-induced differ-
entiation of the cells (Figure 4). The prenylation of H-ras,
K-ras, and N-ras in the cells is effectively inhibited under the
conditions tested (Figure 5). This result suggested that far-
nesylated proteins, such as H-ras, K-ras, and N-ras, could be
implied in the mechanism of cell differentiation by ATRA.
DISCUSSION
At 50nM, ATRA exhibited 34.9% and 73% of cell differ-
entiationincontrolandcompactin-treatedcells,respectively.
A 24hours treatment of HL-60 cells by compactin, a potent
HMG-CoA reductase inhibitor, increased their sensitivity to
ATRA.Infact,HMG-CoAreductaseisoneof themosthighly
regulated enzymes. Compactin is well known as inducing an
overexpression of reductase protein. In cultured cells, com-112 Naima Gueddaria-Pouzols et al. 1:3 (2001)
pactinblocksthesynthesisofMVAandtriggersadaptivereac-
tionsthatyielda200-foldincreaseinreductaseproteinwithin
a few hours [11]. After removal of compactin, this enzyme
becomes active, boosts the mevalonate pathway with con-
comitant increase of the sterol and nonsterol products [11].
The increase of ATRA differentiating activity in compactin-
treated cells could be therefore a consequence of an increase
in the sterol or nonsterol compounds or both.
A ﬁrst attempt was made to check the effect of an excess
of cholesterol supply. Increasing concentrations of LDL (up
to 80 µg/ml) enhanced growth inhibition and decreased cell
differentiation induced by 1µM of ATRA (Figure 3). In the
twocases,alimitwasreachedandthiscouldbeaconsequence
of theremainingactivityof endogenousmevalonatepathway
[11].HL-60cellshavenumerousreceptorsforLDLwhichcan
therefore deliver cholesterol to the cells [32]. The inhibitory
effects could be attributed to the decrease of the nonsterol
products.
To conﬁrm the effect of nonsterol products, on cell
differentiation,HL-60cellswerepreincubatedwiththepreny-
lation inhibitors. In the presence of FTI-II, FTI-277 spe-
ciﬁc inhibitors for farnesyltransferase, ATRA differentiating
activity can be totally abolished. By contrast, GGTI-298 has
no signiﬁcant effect. Comparison of the results conﬁrm a
predominant role for farnesylation (inhibited by FT-277)
comparedwithgeranygeranylation(inhibitedbyGGTI-298).
A less speciﬁc inhibitor FTI-II, acting on the two types of
isoprenoid compounds, has less pronounced effects. West-
ern blots electrophoresis conﬁrms that, at the concentration
used, farnesylation and geranygeranylation reactions were
actually inhibited.
FarnesylproteinsincludeRasproteinsthatareinvolvedin
thetransductionof mitogenicsignals.Inaddition,ourresults
show that compounds of the farnesyl proteins family includ-
ing H-ras, N-ras, and K-ras could be involved in the retinoic
acid-induced differentiation of HL-60 cells. Figure 6 shows
the regulation of HMG-CoA reductase activity and the role
of farnesylated proteins on growth and cell differentiation.
ATRA is well known to act up on these processes but, in ad-
dition, our results show that farnesyl proteins play a key role
in theATRA-induced differentiation of HL-60 cells.A mech-
anism, involving RAR and/or RXR retinoic acid receptors,
cannot be excluded but requires further investigations.
Takentogether,theseresults(i)suggestedtheinvolvement
of mevalonatepathwayinATRAdifferentiatingeffectonHL-
60 cells, and (ii) support the use of HMG-CoA reductase
inhibitors as potential adjuvant therapeutic agents in differ-
entiating chemotherapy.
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